SANOFI Sanofi India Q2 FY26 results (Jul–Sep 2025) and concall
Sanofi India reported a strong Q3 FY26, driven by robust growth in its diabetes and partnership segments, coupled with significant OPEX optimization that led to improved PBT margins. The company declared an interim dividend of INR 75 per share. While export sales faced a decline due to a prior divestment, management is actively mitigating this through new market entries and internal efficiencies, with minimal impact on overall profit due to lower export margins. The strategic focus remains on accelerating the insulin portfolio and leveraging AI for operational excellence.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 9.4%, net profit down 7.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 524 | 515 | 536 | 406 | 475 −9% |
| EBITDA | 120 | 118 | 172 | 95 | 134 +12% |
| Net profit | 82 | 91 | 120 | 70 | 76 −7% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
